Press Release

Oculis and European Biotech Acquisition Corp. Announce Business Combination Agreement

October 25, 2022

London – October 25, 2022 – Cooley served as US legal counsel to Oculis in its business combination with European Biotech Acquisition Corp. Partners Michal Berkner, Div Gupta, Ryan Sansom and Aaron Pomeroy led the Cooley team.

The new company will be known as Oculis Holding, and it is expected to have a post-transaction enterprise value of approximately $220 million and a cash balance exceeding $200 million, including a gross private investment in public equity (PIPE) and private investment of close to $80 million.

Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address medical needs with breakthrough innovations. Headquartered in Lausanne, Switzerland, with operations in Europe, the US and China, Oculis is led by an experienced management team that has an extensive track record and is supported by leading international healthcare investors.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of 3,300.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.